Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) Return on Capital Employed (2016 - 2025)

Guided Therapeutics' Return on Capital Employed history spans 14 years, with the latest figure at 42.95% for Q4 2025.

  • On a quarterly basis, Return on Capital Employed fell 61.0% to 42.95% in Q4 2025 year-over-year; TTM through Dec 2025 was 42.95%, a 61.0% decrease, with the full-year FY2025 number at 44.88%, down 63.0% from a year prior.
  • Return on Capital Employed hit 42.95% in Q4 2025 for Guided Therapeutics, up from 39.58% in the prior quarter.
  • Over the last five years, Return on Capital Employed for GTHP hit a ceiling of 427.0% in Q1 2023 and a floor of 22.15% in Q1 2021.
  • Historically, Return on Capital Employed has averaged 97.87% across 5 years, with a median of 55.27% in 2021.
  • Biggest five-year swings in Return on Capital Employed: soared 36926bps in 2023 and later plummeted -34797bps in 2024.
  • Tracing GTHP's Return on Capital Employed over 5 years: stood at 60.65% in 2021, then surged by 339bps to 266.45% in 2022, then plummeted by -57bps to 113.83% in 2023, then plummeted by -62bps to 43.56% in 2024, then dropped by -1bps to 42.95% in 2025.
  • Business Quant data shows Return on Capital Employed for GTHP at 42.95% in Q4 2025, 39.58% in Q3 2025, and 41.89% in Q2 2025.